ArticleKidney medicine2026
Open-label Randomized Controlled Trial of Controlled-release Formulation Budesonide in Indian Proteinuric IgA Nephropathy Patients.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enteric and Controlled-Release Budesonide in IgA Nephropathy: Expanding Access While Refining Evidence.Kidney international reports · 2026Article
- Generic Controlled-Release Budesonide in IgA Nephropathy - A Single Center Retrospective Study.Kidney international reports · 2026Article
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: IgA nephropathy (IgAN) in India is reported to have an onset at a younger age with faster progression to kidney failure requiring replacement therapy, where safe immunosuppression may improve the outcome. The gut-renal connection and multihit pathogenesis of IgAN targeted by an oral targeted-release formulation of budesonide available in the Western world showed that the molecule is safe and effective. In this study, we aimed to assess the safety and efficacy of oral controlled-release budesonide preparation in Indian patients with IgAN. Methods: We report a single-center open-label randomized controlled trial conducted in a tertiary care hospital in Eastern India, where adult patients with biopsy-proven IgAN with proteinuria > 1 g and estimated glomerular filtration rate (eGFR) > 45 mL/min/1.73 m Results: All baseline parameters, including blood pressure, glycemic status, 24-hour urine protein levels, and eGFR, were comparable in both arms. At the end of 9 months, the mean 24-hour proteinuria was lower ( Conclusions: Controlled-release budesonide may be considered an effective and safe disease-specific therapy in Indian patients with IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.